Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
GSK's RSV vaccine gets expanded approval in Europe
(Sharecast News) - GSK announced on Thursday that the European Commission had granted approval for Arexvy, a respiratory syncytial virus (RSV) vaccine, to be used in adults aged 50 to 59 who were at heightened risk of severe RSV-related illness. The FTSE 100 pharmaceuticals giant said the expanded indication was the first time a vaccine had been authorised in Europe to protect the age group from lower respiratory tract disease (LRTD) caused by RSV.
It said the approval was particularly significant given that around 20 million adults in the 50 to 59 age bracket across 30 European countries had underlying health conditions, such as chronic obstructive pulmonary disease (COPD), asthma, heart failure, or diabetes, increasing their vulnerability to severe outcomes from RSV.
The decision by the European Commission followed earlier approvals for the vaccine's use in adults aged 60 and over in Europe and a similar authorisation in the United States.
GSK said it had also submitted regulatory filings in Japan and other regions to extend the vaccine's use.
The European Commission's approval was supported by positive phase three trial results, demonstrating the vaccine's safety and efficacy in adults aged 50 to 59, including those with underlying medical conditions.
Further trials were underway to evaluate the vaccine's effectiveness in younger adults and immunocompromised individuals, with results expected later in the year.
"Today's approval reflects the importance of broadening the benefits of RSV immunisation to adults aged 50 to 59 who are at increased risk," said GSK chief scientific officer Tony Wood.
"RSV infection can have a significant impact on the health of older adults and particularly those with certain existing medical conditions, which can add pressure onto healthcare systems.
"As we enter the RSV season, we are pleased to be the first to deliver a vaccine to help protect more people in Europe from RSV-LRTD."
At 0834 BST, shares in GSK were up 0.58% at 1,661p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
